Cargando…
rhErythropoietin-b as a tissue protective agent in kidney transplantation: a pilot randomized controlled trial
BACKGROUND: Extended criteria donor (ECD) and donation after circulatory death (DCD) kidneys are at increased risk of delayed graft function (DGF). Experimental evidence suggests that erythropoietin (EPO) attenuates renal damage in acute kidney injury. This study piloted the administration of high d...
Autores principales: | Coupes, Beatrice, de Freitas, Declan G, Roberts, Stephen A, Read, Ian, Riad, Hany, Brenchley, Paul EC, Picton, Michael L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4330593/ https://www.ncbi.nlm.nih.gov/pubmed/25643790 http://dx.doi.org/10.1186/s13104-014-0964-0 |
Ejemplares similares
-
Activation of transforming growth factor-β(1 )and early atherosclerosis in systemic lupus erythematosus
por: Jackson, Michelle, et al.
Publicado: (2006) -
Comparative Study of Recombinant Human Erythropoietin (rhEPO)
Products on CKD (Chronic Kidney Disease) Patients
por: Dwitanto, Kuspuji, et al.
Publicado: (2023) -
Erythropoietin stimulating agents in the management of anemia of chronic kidney disease
por: Hayat, Amir, et al.
Publicado: (2008) -
Erythropoietin: a multimodal neuroprotective agent
por: Byts, Nadiya, et al.
Publicado: (2009) -
Development of an erythropoietin prescription simulator to improve abilities for the prescription of erythropoietin stimulating agents: Is it feasible?
por: Gabutti, Luca, et al.
Publicado: (2011)